Risk and prognostic factors of breast cancer with liver metastases

• Published in: BMC cancer 2021-03, Vol.21 (1), p.238-238, Article 238
• Main Authors: Ji, Lei, Cheng, Lei, Zhu, Xiuzhi, Gao, Yu, Fan, Lei, Wang, Zhonghua
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Breast - pathology; Breast cancer; Breast Neoplasms - mortality; Breast Neoplasms - pathology; Breast Neoplasms - therapy; Carcinoma, Ductal, Breast - epidemiology; Carcinoma, Ductal, Breast - secondary; Carcinoma, Ductal, Breast - therapy; Care and treatment; Chemoradiotherapy, Adjuvant - methods; Complications and side effects; Datasets; Datasets as Topic; Development and progression; Disease; Epidemiology; Epidermal growth factor; ErbB-2 protein; Evaluation; Female; Follow-Up Studies; HER2-targeted therapy; Humans; Incidence; Invasiveness; Kaplan-Meier Estimate; Liver; Liver - diagnostic imaging; Liver - pathology; Liver cancer; Liver metastasis; Liver Neoplasms - epidemiology; Liver Neoplasms - secondary; Liver Neoplasms - therapy; Mastectomy; Medical prognosis; Metastases; Metastasis; Middle Aged; Mortality; Neoadjuvant Therapy - methods; Prognosis; Prognostic factors; Receptor, ErbB-2 - analysis; Receptor, ErbB-2 - antagonists & inhibitors; Receptor, ErbB-2 - metabolism; Receptors, Estrogen - analysis; Receptors, Estrogen - metabolism; Receptors, Progesterone - analysis; Receptors, Progesterone - metabolism; Regression analysis; Retrospective Studies; Risk Factors; Survival; Treatment Outcome; Triple Negative Breast Neoplasms - mortality; Triple Negative Breast Neoplasms - pathology; Triple Negative Breast Neoplasms - therapy; Tumors; Young Adult
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-021-07968-5

Liver metastasis is a significant adverse predictor of overall survival (OS) among breast cancer patients. The purpose of this study was to determine the risk and prognostic factors of breast cancer with liver metastases (BCLM). Data on 311,573 breast cancer patients from the Surveillance, Epidemiology, and End Results (SEER) database and 1728 BCLM patients from Fudan University Shanghai Cancer Center (FUSCC) were included. Logistic regression was used to identify risk factors for liver metastasis. Cox proportional hazards regression model was adopted to determine independent prognostic factors in BCLM patients. Young age, invasive ductal carcinoma, higher pathological grade, and subtype of triple-negative and human epidermal growth factor receptor 2 positive (HER2+) were risk factors for developing liver metastasis. The median OS after liver metastasis was 20.0 months in the SEER database and 27.3 months in the FUSCC dataset. Molecular subtypes also played a critical role in the survival of BCLM patients. We observed that hormone receptor-positive (HR+)/HER2+ patients had the longest median OS (38.0 for SEER vs. 34.0 months for FUSCC), whereas triple-negative breast cancer had the shortest OS (9.0 vs. 15.6 months) in both SEER and FUSCC. According to the results from the FUSCC, the subtype of HR+/HER2+ (hazard ratio (HR) = 2.62; 95% confidence interval (CI) = 1.88-3.66; P